In an age where medical misinformation spreads faster than peer-reviewed research, trust in healthcare innovation is under siege. While skepticism toward unproven therapies is justified, it’s essential not to conflate scientific exploration with pseudoscience. At Astron Health, we aim to answer some of the most difficult questions in cancer biology—not with conjecture, but through clinical trials, molecular data, and rigorous evidence.
For patients and clinicians navigating complex diseases like pancreatic cancer, innovation must remain grounded in science and measurable outcomes, not empty promises.
The Problem We’re Solving: A Gap in Oncology Treatment
Pancreatic adenocarcinoma, one of the deadliest cancers, exemplifies where current standards of care often fall short:
- Even after surgery, MRD (Minimal Residual Disease) leaves patients at high risk of relapse.
- Conventional therapies have very limited efficacy, leaving oncologists and patients with limited options.
Astron Health seeks to change that by identifying real-time molecular vulnerabilities in cancer cells—using advanced genomics, transcriptomics, cytotoxicity testing, and pathway analysis—to design personalized adjunctive treatment protocols using safe, tolerable and cheap drugs/supplements.We don’t claim to replace standard treatments; we seek to enhance them, addressing gaps where the data compels us to look.
How We Do It: Precision Meets Rigour
1. Data-Driven Precision Medicine
Our approach relies on:
- Multi-Omics Profiling: Whole transcriptome analysis, genomic testing, and functional cytotoxicity data to uncover tumour-specific vulnerabilities.
- Pathway Insights: Tools like KEGG pathway enrichment allow us to prioritize therapies targeting key oncogenic drivers (e.g., PI3K/AKT, glycolysis).
- Repurposed Therapies: Drugs and supplements like metformin, statins, or aspirin—well-studied in other diseases—offer low-cost, scientifically plausible adjunctive options that require formal validation.
2. The Scientific Method
Astron Health firmly believes in the gold standard: clinical trials.
- Our upcoming trials in MRD-positive pancreatic cancer will rigorously test adjunctive treatments to improve disease-free survival.
- Outcomes will be measured objectively using markers like ctDNA clearance, validated endpoints (DFS, OS), and patient quality of life.
Every step is transparent, data-driven, and grounded in clinical science. If a hypothesis doesn’t hold up under scrutiny, we move on.
Innovation, Not Misinformation
We understand the dangers of misinformation—unproven therapies harm patients and erode trust. At Astron Health:
- We do not make claims without evidence. Every adjunctive therapy we recommend will undergo clinical validation.
- We recognize the fine line between curiosity and false hope. Innovation, when grounded in science, can bring genuine breakthroughs to patients.
The medical community must remain open to testing non-traditional approaches where existing therapies fail. Science is not dogma—it’s a process of exploration, validation, and refinement.
Our Call to Action: Collaboration Over Controversy
At Astron Health, we invite collaboration with oncologists, researchers, and institutions who share our mission:
- To explore scientifically plausible adjunctive therapies with some preclinical or real-world data.
- To rigorously test them through trials.
- To deliver personalized treatment strategies that improve patient outcomes where others have struggled.
The conversation shouldn’t be “innovation vs. standard care”—it should be “evidence-based innovation, working alongside standard of care.”
A Vision for the Future
Innovation can—and must—be both bold and responsible. At Astron Health, we believe it is our duty to challenge existing paradigms in cancer treatment while upholding the principles of science, transparency, and clinical rigor.For patients and oncologists navigating the toughest cancers, we aim to provide data-driven answers to the questions no one else is asking.
Next Steps
- Clinicians: Collaborate with us to refine and validate adjunctive therapies in clinical trials.
- Researchers: Partner with us to analyze multi-omics data and co-publish findings.
Patients: Know that innovation, when validated, can offer new hope without compromising scientific integrity.
Astron is a research organization focused on advancing precision oncology through multiple lenses. We provide reports to patients under the guidance of their referring oncologist, where clinicians believe our insights may support patient care. If you’re a patient interested in our research or reports, please speak
Astron Health Blog 
Leave a comment